Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

LYEL - Lyell Immunopharma, Inc. Последние новости | Finranks

Home

LYEL

(LYEL)

NMS – Цена в реальном времени. Валюта: USD

19.67

-0.55 (-2.72%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

20.06

+0.39 (1.98%)

После закрытия: Mar 27, 2026, 5:39 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient dosing in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial of rondecabtagene autoleucel (ronde-cel) versus investigator's choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with disease progression on at least one prior line of therapy (PiNACLE-H2H). Lyell has dosed seven new patients with metastatic colorectal cancer (mCRC) with LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, since its November 2025 acquisition, without dose-limiting toxicity and including dose escalation to Dose Level 3.

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL) in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026.

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern Time Leerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern Time Citizens Life Science Conference on Tuesday, March 10, 2026, in Miami, Florida; fireside chat at 11:55am Eastern Time A live webcast of each presentation can be accessed through the Investors section of the Company's website at www.lyell.com.

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that the first patient has been dosed in the PiNACLE – H2H Phase 3 trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line (2L) setting.

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar

Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.

Видео

No Data

There is no data to display